Stephen H Leppla

US Patent:

6485925, Nov 26, 2002

Filed:

Dec 13, 2000

Appl. No.:

09/623104

Inventors:

Nicholas Duesbery - Grand Rapids MI
Craig Webb - Rockford MI
Stephen Leppla - Bethesda MD
George Vande Woude - Ada MI

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12Q 137

US Classification:

435 23, 536 231, 536 232, 435 71, 435 721, 435 723, 435 6

Abstract:

The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.

US Patent:

6592872, Jul 15, 2003

Filed:

Sep 15, 1997

Appl. No.:

08/937276

Inventors:

Kurt Klimpel - San Diego CA
Theresa J. Goletz - Kensington MD
Naveen Arora - Delhi, IN
Stephen H. Leppla - Bethesda MD
Jay A. Berzofsky - Bethesda MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 3907

US Classification:

42419711, 4241831, 4241921, 4242361, 4242461, 4241841, 4241931, 42419511, 514 2, 514885, 530350, 530323, 530403, 530402, 530806, 530825

Abstract:

The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine comprising an anthrax protective antigen and a full length protein antigen bound to a nontoxic anthrax protective antigen binding protein comprising at least about the first 250 amino acid residues of the lethal factor of and less than all of the amino acid residues of the lethal factor. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.

US Patent:

6893835, May 17, 2005

Filed:

Mar 5, 2002

Appl. No.:

10/093248

Inventors:

Nicholas Duesbery - Grand Rapids MI, US
Craig Webb - Rockford MI, US
Stephen Leppla - Bethesda MD, US
George Vande Woude - Ada MI, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12Q001/37
C12N009/54

US Classification:

435 23, 435221

Abstract:

The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.

US Patent:

6911203, Jun 28, 2005

Filed:

Mar 5, 2002

Appl. No.:

10/093200

Inventors:

Nicholas Duesbery - Grand Rapids MI, US
Craig Webb - Rockford MI, US
Stephen Leppla - Bethesda MD, US
George Vande Woude - Ada MI, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K038/46
A01N063/00
C12N009/52
C12N015/63
C12Q001/40

US Classification:

424 9467, 435220, 435 23, 4353201, 435325, 435455, 435458, 4353873, 424 931

Abstract:

The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.

US Patent:

7056693, Jun 6, 2006

Filed:

Apr 22, 2005

Appl. No.:

11/112137

Inventors:

Nicholas Duesbery - Grand Rapids MI, US
Craig Webb - Rockford MI, US
Stephen Leppla - Bethesda MD, US
George Vande Woude - Ada MI, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12Q 1/37
C12Q 1/00

US Classification:

435 23, 435 4, 435194

Abstract:

The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.

US Patent:

7097965, Aug 29, 2006

Filed:

May 27, 2003

Appl. No.:

10/446890

Inventors:

Kurt Klimpel - San Diego CA, US
Theresa J. Goletz - Kensington MD, US
Naveen Arora - Delhi, IN
Stephen H. Leppla - Bethesda MD, US
Jay A. Berzofsky - Bethesda MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12N 5/00
C07K 19/00

US Classification:

435 2, 435375, 530403, 530806, 4241931, 4241921, 42419711

Abstract:

The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary toxin protective antigen and the antigen, which is bound to a binary toxin protective antigen binding protein. In one embodiment the vaccine is comprised of an anthrax protective antigen and the antigen bound to anthrax protective antigen binding protein. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.

US Patent:

7183071, Feb 27, 2007

Filed:

Jan 5, 2006

Appl. No.:

11/326985

Inventors:

Nicholas Duesbery - Grand Rapids MI, US
Craig Webb - Rockford MI, US
Stephen Leppla - Bethesda MD, US
George Vande Woude - Ada MI, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

G01N 33/567
G01N 33/53
C12Q 1/37
C12N 9/54
C12N 9/12

US Classification:

435 23, 435221, 435194, 435 723, 435 74, 435 721

Abstract:

The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.

US Patent:

7468352, Dec 23, 2008

Filed:

Sep 22, 2000

Appl. No.:

10/088952

Inventors:

Stephen H. Leppla - Bethesda MD, US
Henning Birkedal-Hansen - Bethesda MD, US
Thomas Bugge - Bethesda MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 38/00

US Classification:

514 12

Abstract:

The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.